Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: TKI, . Treffer: 32

2022

Bolsterli, BK; Boltshauser, E; Palmieri, L; Spenger, J; Brunner-Krainz, M; Distelmaier, F; Freisinger, P; Geis, T; Gropman, AL; Haberle, J; Hentschel, J; Jeandidier, B; Karall, D; Keren, B; Klabunde-Cherwon, A; Konstantopoulou, V; Kottke, R; Lasorsa, FM; Makowski, C; Mignot, C; Tuura, RO; Porcelli, V; Santer, R; Sen, K; Steinbrucker, K; Syrbe, S; Wagner, M; Ziegler, A; Zoggeler, T; Mayr, JA; Prokisch, H; Wortmann, SB Ketogenic Diet Treatment of Defects in the Mitochondrial Malate Aspartate Shuttle and Pyruvate Carrier
NUTRIENTS. 2022; 14(17): 3605 Doi: 10.3390/nu14173605 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Fluhrer, H; Hutterer, GC; Golbeck, S; Stidl, M; Niedrist, T; Pichler, R; Mischinger, J; Seles, M; Mannweiler, S; Spiegelberg, J; Bauernhofer, T; Jost, PJ; Ahyai, S; Zigeuner, R; Pichler, M; Barth, DA Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.
Ther Adv Med Oncol. 2022; 14: 17588359221134065 Doi: 10.1177/17588359221134065 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

2021

Buder, A; Heitzer, E; Waldispühl-Geigl, J; Weber, S; Moser, T; Hochmair, MJ; Hackner, K; Errhalt, P; Setinek, U; Filipits, M Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.
BIOMOLECULES. 2021; 11(5): Doi: 10.3390/biom11050618 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Eichler, M; Pink, D; Menge, F; Jakob, J; Hentschel, L; Richter, S; Hohenberger, P; Kasper, B; Andreou, D; Singer, S; Grützmann, R; Dmytrow, DI; Arndt, K; Tuchscherer, A; Reichardt, P; Ahrens, M; Kunitz, A; Mohm, J; Bornhäuser, M; Schmitt, J; Schuler, MK Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa).
Eur J Cancer Care (Engl). 2021; 30(6):e13484 Doi: 10.1111/ecc.13484
Web of Science PubMed FullText FullText_MUG

 

Illini, O; Hochmair, MJ; Fabikan, H; Weinlinger, C; Tufman, A; Swalduz, A; Lamberg, K; Hashemi, SMS; Huemer, F; Vikstrom, A; Wermke, M; Absenger, G; Addeo, A; Banerji, S; Calles, A; Clarke, S; Di Maio, M; Durand, A; Duruisseaux, M; Itchins, M; Kaaranien, OS; Krenn, F; Laack, E; de Langen, AJ; Mohorcic, K; Pall, G; Passaro, A; Prager, G; Rittmeyer, A; Rothenstein, J; Schumacher, M; Woll, E; Valipour, A Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
THER ADV MED ONCOL. 2021; 13: 17588359211019675 Doi: 10.1177/17588359211019675 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Laskaratos, FM; Levi, A; Schwach, G; Pfragner, R; Hall, A; Xia, D; von Stempel, C; Bretherton, J; Thanapirom, K; Alexander, S; Ogunbiyi, O; Watkins, J; Luong, TV; Toumpanakis, C; Mandair, D; Caplin, M; Rombouts, K Transcriptomic Profiling of In Vitro Tumor-Stromal Cell Paracrine Crosstalk Identifies Involvement of the Integrin Signaling Pathway in the Pathogenesis of Mesenteric Fibrosis in Human Small Intestinal Neuroendocrine Neoplasms.
Front Oncol. 2021; 11(6):629665-629665 Doi: 10.3389/fonc.2021.629665 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Scheipl, S; Barnard, M; Lohberger, B; Zettl, R; Brcic, I; Liegl-Atzwanger, B; Rinner, B; Meindl, C; Fröhlich, E Drug combination screening as a translational approach toward an improved drug therapy for chordoma.
Cell Oncol (Dordr). 2021; 44(6):1231-1242 Doi: 10.1007/s13402-021-00632-x [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Smolle, E; Taucher, V; Lindenmann, J; Jost, PJ; Pichler, M Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer.
Cancers (Basel). 2021; 13(4): Doi: 10.3390/cancers13040699 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Stitz, R; Buder, A; Silye, R; Baumgartner, B; Pühringer, F; Filipits, M; Oberndorfer, E; Heitzer, E Validation of a next-generation sequencing assay for the detection of EGFR mutations in cell-free circulating tumor DNA.
EXP MOL PATHOL. 2021; 123: 104685 Doi: 10.1016/j.yexmp.2021.104685
Web of Science PubMed FullText FullText_MUG

 

2020

Hähnel, T; Baldow, C; Guilhot, J; Guilhot, F; Saussele, S; Mustjoki, S; Jilg, S; Jost, PJ; Dulucq, S; Mahon, FX; Roeder, I; Fassoni, AC; Glauche, I Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML.
Cancer Res. 2020; 80(11):2394-2406 Doi: 10.1158/0008-5472.CAN-19-2175
Web of Science PubMed FullText FullText_MUG

 

Petzer, AL; Sperr, WR; Buxhofer-Ausch, V; Sliwa, T; Schmidt, S; Greil, R; Wölfler, A; Pichler, P; Dormann, C; Burgstaller, S; Tinchon, C; Lang, A; Goebel, F; Uthman, S; Muenchmeier, N; Valent, P A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study.
Wien Klin Wochenschr. 2020; Doi: 10.1007/s00508-020-01690-1 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Schwaab, J; Naumann, N; Luebke, J; Jawhar, M; Somervaille, TCP; Williams, MS; Frewin, R; Jost, PJ; Lichtenegger, FS; La Rosée, P; Storch, N; Haferlach, T; Horny, HP; Fabarius, A; Haferlach, C; Burchert, A; Hofmann, WK; Cross, NCP; Hochhaus, A; Reiter, A; Metzgeroth, G Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
Am J Hematol. 2020; 95(7):824-833 Doi: 10.1002/ajh.25825 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2019

Hochmair, MJ; Weinlinger, C; Fabikan, H; Illini, O; Krenbek, D; Setinek, U; Watzka, S; Koger, R; Meilinger, M; Absenger, G; Wanke, M; Semmelweis, C; Rauter, M; Valipour, A Treatment Observations and Clinical Experience with Lorlatinib in Pretreated ALK and ROS1 Rearranged NSCLC Patients
J THORAC ONCOL. 2019; 14(10):S847-S847. Doi: 10.1016/j.jtho.2019.08.1831 [Poster]
Web of Science FullText FullText_MUG

 

Scheipl, S; Liegl-Atzwanger, B; Szkandera, J; Rinner, B; Viertler, C; Friesenbichler, J; Bergovec, M; Leithner, A [Is there a magic bullet for sarcomas? : Personalised treatment for maligant tumours of bone and soft tissue].
Orthopade. 2019; 48(9): 776-783. Doi: 10.1007/s00132-019-03790-x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Stecher, M; Hoenigl, M; Eis-Hübinger, AM; Lehmann, C; Fätkenheuer, G; Wasmuth, JC; Knops, E; Vehreschild, JJ; Mehta, S; Chaillon, A Hotspots of Transmission Driving the Local Human Immunodeficiency Virus Epidemic in the Cologne-Bonn Region, Germany.
Clin Infect Dis. 2019; 68(9):1539-1546 Doi: 10.1093/cid/ciy744 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2018

Buder, A; Hochmair, MJ; Schwab, S; Bundalo, T; Schenk, P; Errhalt, P; Mikes, RE; Absenger, G; Patocka, K; Baumgartner, B; Setinek, U; Burghuber, OC; Prosch, H; Pirker, R; Filipits, M Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.
J Thorac Oncol. 2018; 13(6):821-830 Doi: 10.1016/j.jtho.2018.02.014 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Krug, S; Abbassi, R; Griesmann, H; Sipos, B; Wiese, D; Rexin, P; Blank, A; Perren, A; Haybaeck, J; Hüttelmaier, S; Rinke, A; Gress, TM; Michl, P Therapeutic Targeting of Tumor-Associated Macrophages in Pancreatic Neuroendocrine Tumors.
Int J Cancer. 2018; Doi: 10.1002/ijc.31562 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Moll, HP; Pranz, K; Musteanu, M; Grabner, B; Hruschka, N; Mohrherr, J; Aigner, P; Stiedl, P; Brcic, L; Laszlo, V; Schramek, D; Moriggl, R; Eferl, R; Moldvay, J; Dezso, K; Lopez-Casas, PP; Stoiber, D; Hidalgo, M; Penninger, J; Sibilia, M; Győrffy, B; Barbacid, M; Dome, B; Popper, H; Casanova, E Afatinib restrains K-RAS-driven lung tumorigenesis.
Sci Transl Med. 2018; 10(446): Doi: 10.1126/scitranslmed.aao2301 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Rinaldetti, S; Pfirrmann, M; Manz, K; Guilhot, J; Dietz, C; Panagiotidis, P; Spiess, B; Seifarth, W; Fabarius, A; Müller, M; Pagoni, M; Dimou, M; Dengler, J; Waller, CF; Brümmendorf, TH; Herbst, R; Burchert, A; Janβen, C; Goebeler, ME; Jost, PJ; Hanzel, S; Schafhausen, P; Prange-Krex, G; Illmer, T; Janzen, V; Klausmann, M; Eckert, R; Büschel, G; Kiani, A; Hofmann, WK; Mahon, FX; Saussele, S Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.
Clin Lymphoma Myeloma Leuk. 2018; 18(4):266-271 Doi: 10.1016/j.clml.2018.02.004 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Schneider, C; Wallner, M; Kolesnik, E; Herbst, V; Mächler, H; Pichler, M; von Lewinski, D; Sedej, S; Rainer, PP The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients.
Sci Rep. 2018; 8(1):5295-5295 Doi: 10.1038/s41598-018-23630-w [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2017

Hochmair, M; Holzer, S; Filipits, M; Mohn-Staudner, A; Errhalt, P; Absenger, G; Bundalo, T; Arns, M; Setinek, U; Mikes, R; Kolb, R; Schumacher, M; Zochbauer-Muller, S; Patocka, K; Haslbauer, F; Rudzki, J; Burghuber, O EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib
J THORAC ONCOL. .. 2017; 12(1):S1254-S1254. Doi: 10.1016/j.jtho.2016.11.1769 [Poster]
Web of Science FullText FullText_MUG

 

2016

Beinhardt, S; Al Zoairy, R; Ferenci, P; Kozbial, K; Freissmuth, C; Stern, R; Stättermayer, AF; Stauber, R; Strasser, M; Zoller, H; Watschinger, B; Schmidt, A; Trauner, M; Hofer, H; Maieron, A DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
Transpl Int. 2016; 29(9):999-1007 Doi: 10.1111/tri.12799 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Preuner, S; Barna, A; Frommlet, F; Czurda, S; Konstantin, B; Alikian, M; Machova Polakova, K; Sacha, T; Richter, J; Lion, T; Gabriel, C Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches.
Int J Mol Sci. 2016; 17(5): Doi: 10.3390/ijms17050642 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2014

Kastner, R; Zopf, A; Preuner, S; Pröll, J; Niklas, N; Foskett, P; Valent, P; Lion, T; Gabriel, C Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.
Eur J Cancer. 2014; 50(4): 793-800. Doi: 10.1016/j.ejca.2013.11.030 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Pircher, A; Manzl, C; Fiegl, M; Popper, H; Pirker, R; Hilbe, W Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Lung Cancer. 2014; 83(3): 408-410. Doi: 10.1016/j.lungcan.2013.12.007 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

2013

Opatz, S; Polzer, H; Herold, T; Konstandin, NP; Ksienzyk, B; Zellmeier, E; Vosberg, S; Graf, A; Krebs, S; Blum, H; Hopfner, KP; Kakadia, PM; Schneider, S; Dufour, A; Braess, J; Sauerland, MC; Berdel, WE; Büchner, T; Woermann, BJ; Hiddemann, W; Spiekermann, K; Bohlander, SK; Greif, PA Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.
Blood. 2013; 122(10): 1761-1769. Doi: 10.1182/blood-2013-01-476473
Web of Science PubMed FullText FullText_MUG

 

2012

Valent, P; Gastl, G; Geissler, K; Greil, R; Hantschel, O; Lang, A; Linkesch, W; Lion, T; Petzer, AL; Pittermann, E; Pleyer, L; Thaler, J; Wolf, D Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions.
Crit Rev Oncol Hematol. 2012; 82(3):370-377 Doi: 10.1016/j.critrevonc.2011.08.002
Web of Science PubMed FullText FullText_MUG

 

2011

Popper, H; Wrba, F; Gruber-Mösenbacher, U; Hulla, W; Pirker, R; Hilbe, W; Studnicka, M; Mohn-Staudner, A; Ploner, F; und die Arbeitsgruppe Pulmopathologie der ÖGP-IAP Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer.
Wien Klin Wochenschr. 2011; 123(9-10):316-321 Doi: 10.1007/s00508-011-1573-8
Web of Science PubMed FullText FullText_MUG

 

Watzka, SB; Posch, F; Hochmair, M; Setinek, U; Köstler, WJ; Müller, MR Resistance to EGFR targeting therapies in lung cancer.
Minerva Chir. 2011; 66(5): 483-494.
Web of Science PubMed

 

2010

Pircher, A; Ploner, F; Popper, H; Hilbe, W Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients.
Lung Cancer. 2010; 69(3): 265-271. Doi: 10.1016/j.lungcan.2010.01.017
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Schmidt, S; Wolf, D; Thaler, J; Burgstaller, S; Linkesch, W; Petzer, A; Fridrik, M; Lang, A; Agis, H; Valent, P; Krieger, O; Walder, A; Korger, M; Schlögl, E; Sliwa, T; Wöll, E; Mitterer, M; Eisterer, W; Pober, M; Gastl, G; on behalf of the ASHO CML registry First annual report of the Austrian CML registry.
Wien Klin Wochenschr. 2010; 122(19-20): 558-566. Doi: 10.1007/s00508-010-1450-x
Web of Science PubMed FullText FullText_MUG

 

2008

Liegl, B; Kepten, I; Le, C; Zhu, M; Demetri, GD; Heinrich, MC; Fletcher, CD; Corless, CL; Fletcher, JA Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
J Pathol. 2008; 216(1): 64-74. Doi: 10.1002/path.2382 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

© Med Uni Graz Impressum